Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2024/043249
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a cyclic peptide or salt thereof having excellent cell membrane permeability and excellent target bindability with MDMX, and an MDMX inhibitor. The present invention provides a cyclic peptide, or a salt thereof, which is represented by formula (1) defined in the specification of the present application, and which has features (a)-(d) below. (a) The cyclic peptide has a structure in which, when a is taken to be the axial length in the axial direction of the longest main chain structure and b and c are taken to be the axial lengths in two other directions which are orthogonal to a and orthogonal to each other, and the ellipsoid approximation is performed to determine the axial lengths for a, b, and c, and through this approximation stage, the molecular shape factor r is calculated using formula (2), r ranges from 0.4 to 0.6. (b) The aforementioned peptide is nonionic under a physiological environment. (c) The proportion of the number of N-substituted amino acids to the total number of amino acids in the aforementioned peptide is 25% or more. (d) The aforementioned peptide includes 1-3 amino acid residues and amino acid analogue residues having an aromatic carbocyclic group or an aromatic heterocyclic group in a side chain.

Inventors:
KANEKO MAI (JP)
TAMURA TAKASHI (JP)
SUZUKI KOO (JP)
TSUMURA KYOSUKE (JP)
OHASHI NORIYUKI (JP)
KOCHI MASAHIRO (JP)
HASHIMOTO ICHIHIKO (JP)
MIYAHARA KENTA (JP)
HORIGOME HIROKI (JP)
Application Number:
PCT/JP2023/030222
Publication Date:
February 29, 2024
Filing Date:
August 23, 2023
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
FUJIFILM CORP (JP)
International Classes:
C07K4/00; C07K7/64; C12N15/11
Domestic Patent References:
WO2021102322A12021-05-27
Foreign References:
US20220002346A12022-01-06
Other References:
FURUKAWA, A. ET AL.: "Drug-Like Properties in Macrocycles above MW 1000: Backbone Rigidity versus Side-Chain Lipophilicity", ANGEWANDTE CHEMIE, vol. 59, no. 48, 2020, pages 21571 - 21577, XP072094457, DOI: 10.1002/anie.202004550
PYE, C. R. ET AL.: "Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules", JOURNAL OF MEDICINAL CHEMISTRY, vol. 60, no. 5, 2017, pages 1665 - 1672, XP093142676, DOI: 10.1021/acs.jmedchem.6b01483
FOUCHE, M. ET AL.: "Pharmacokinetic Studies around the Mono-and Difunctionalization of a Bioavailable Cyclic Decapeptide Scaffold", CHEMMEDCHEM, vol. 11, no. 10, 2016, pages 1060 - 1068, XP072415375, DOI: 10.1002/cmdc.201600083
LAWRENCE, N. ET AL.: "Cyclic peptide scaffold with ability to stabilize and deliver a helical cell -impermeable cargo across membranes of cultured cancer cells.", RSC CHEMICAL BIOLOGY, vol. 1, 2020, pages 405 - 420, XP093142681, DOI: 10.1039/d0cb00099j
PARTRIDGE, A. W. ET AL.: "Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties", MOLECULES, vol. 24, no. 12, 2019, pages 2292, XP093142680, DOI: 10.3390/molecules24122292
Attorney, Agent or Firm:
SIKS & CO. (JP)
Download PDF: